An international trial, run in the UK by researchers at the CRUK Southampton Clinical Trials Unit (SCTU) at the Centre for Cancer Immunology, has found that an intensive combination of chemotherapy and immunotherapy can dramatically improve survival for some patients with a rare blood cancer that typically have a very poor outlook.

The MARIETTA study is the largest ever clinical trial looking at the best way to treat secondary central nervous system lymphoma (SCNSL) and results could help contribute to a change in international guidelines on how to treat people the disease. The UK part of the trial was funded by Cancer Research UK’s Stand Up to Cancer campaign and the results are published in Lancet Haematology.

Read more about the study on the SCTU website.